Aggregated
No track record- Bullish
- 3
- Hold
- 0
- Bearish
- 0
Cowen & Co.
A Cowen & Co. analyst with 4 tracked ratings across 4 distinct tickers has a 33.3% success rate on the captured sample, with the most recent rating dated January 25, 2023.
Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.
| Ticker | Date | Rating | Price target | Source |
|---|---|---|---|---|
| KYNB | 2023-02-28 | hold | $25.00 | Aggregated |
| ARGX | 2023-01-25 | buy | $458.00 | Aggregated |
| ARGXARGEN X SE - ADR | 2023-01-25 | unknown | $458.00 | Aggregated |
| TIL | 2022-11-01 | hold | - | Aggregated |
| GMAB | 2022-05-02 | buy | $38.00 | Aggregated |
| GMABGENMAB - ADR | 2022-05-02 | unknown | $38.00 | Aggregated |
| ASND | 2022-01-06 | buy | $136.00 | Aggregated |
| ASNDASCENDIS PHARMA A/S - ADR | 2022-01-06 | unknown | $136.00 | Aggregated |
| ONC | 2021-02-18 | buy | $429.00 | Aggregated |
| Ticker | Ratings | Last rating | Sources |
|---|---|---|---|
| KYNB | 1 | 2023-02-28 | Aggregated |
| ARGX | 2 | 2023-01-25 | Aggregated |
| ARGXARGEN X SE - ADR | 1 | 2023-01-25 | Aggregated |
| TIL | 1 | 2022-11-01 | Aggregated |
| GMAB | 2 | 2022-05-02 | Aggregated |
| GMABGENMAB - ADR | 1 | 2022-05-02 | Aggregated |
| ASND | 2 | 2022-01-06 | Aggregated |
| ASNDASCENDIS PHARMA A/S - ADR | 1 | 2022-01-06 | Aggregated |
| ONC | 1 | 2021-02-18 | Aggregated |